Properties (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
monoclonal antibody
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
vials of 150 mg
vials of 500 mg |
| gptkbp:clinicalTrials |
Phase III
monotherapy NCT01693562 NCT02807636 NCT03390574 PACIFIC trial as part of a combination regimen |
| gptkbp:contraindication |
hepatitis
skin reactions pneumonitis colitis endocrinopathies history of severe allergic reactions nephritis immune-mediated adverse reactions |
| gptkbp:date |
2017
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:dosageForm |
solution for infusion
|
| gptkbp:drugInterdiction |
enhances T-cell activation
half-life of approximately 12 days inhibits_PD-L1_binding_to_PD-1 |
| https://www.w3.org/2000/01/rdf-schema#label |
Durvalumab
|
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:lastProduced |
gptkb:European_Union
gptkb:United_States |
| gptkbp:mandates |
unresectable stage III non-small cell lung cancer
locally advanced or metastatic urothelial carcinoma |
| gptkbp:marketedAs |
Imfinzi
|
| gptkbp:researchFocus |
long-term outcomes
real-world evidence studies patient selection combination with other immunotherapies biomarker_identification |
| gptkbp:route |
IV
|
| gptkbp:safetyFeatures |
post-marketing studies
|
| gptkbp:sells |
Imfinzi
|
| gptkbp:sideEffect |
fatigue
nausea cough diarrhea rash shortness of breath |
| gptkbp:targets |
gptkb:PD-L1
|
| gptkbp:triggerType |
immune checkpoint inhibitor
|
| gptkbp:usedFor |
treatment of bladder cancer
treatment of non-small cell lung cancer |
| gptkbp:worksWith |
chemotherapy
tremelimumab |